426 related articles for article (PubMed ID: 25408130)
1. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
2. Application of flow cytometry for evaluating clinical prognosis and histopathological grade of human glioma.
Lin YW; Tai SH; Chang CC; Chao LC; Wen MJ; Huang YH; Hung HY; Lee EJ
Neurol Res; 2016 Jul; 38(7):625-33. PubMed ID: 27264544
[TBL] [Abstract][Full Text] [Related]
3. DNA ploidy and cell-cycle analysis in intracranial meningiomas and hemangiopericytomas: a study with high-resolution DNA flow cytometry.
Zellner A; Meixensberger J; Roggendorf W; Janka M; Hoehn H; Roosen K
Int J Cancer; 1998 Apr; 79(2):116-20. PubMed ID: 9583723
[TBL] [Abstract][Full Text] [Related]
4. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
5. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 immunostaining and DNA flow cytometry in meningiomas.
Yasue M; Akasaki Y; Numoto TR; Abe S; Abe T; Takeuchi Y; Tanaka J
Noshuyo Byori; 1996 Apr; 13(1):17-20. PubMed ID: 8916122
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
8. Correlation of histopathologic classification with proliferative activity and DNA ploidy in 120 intracranial meningiomas, with special reference to atypical meningioma.
Myong NH; Chi JG
J Korean Med Sci; 1997 Jun; 12(3):221-7. PubMed ID: 9250918
[TBL] [Abstract][Full Text] [Related]
9. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
10. Recurrent and atypical meningiomas--a multiparametric study using Ki67 labelling index, AgNOR and DNA Feulgen staining.
Ferraraccio F; Accardo M; Giangaspero F; Cuccurullo L
Clin Neuropathol; 2003; 22(4):187-92. PubMed ID: 12908755
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
13. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.
Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D
AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
Bruna J; Brell M; Ferrer I; Gimenez-Bonafe P; Tortosa A
Neuropathology; 2007 Apr; 27(2):114-20. PubMed ID: 17494511
[TBL] [Abstract][Full Text] [Related]
15. [DNA analysis of meningiomas using paraffin-embedded surgical specimens in connection with clinical recurrence].
Akachi K; Matsumoto M; Yasue M; Nakamura N; Kamada M; Ohno T
No Shinkei Geka; 1991 Dec; 19(12):1129-34. PubMed ID: 1766537
[TBL] [Abstract][Full Text] [Related]
16. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 index as a predictive marker of meningioma recurrence following surgical resection.
Mizrachi M; Hartley B; Saleem S; Hintz E; Ziemba Y; Li J; Goenka A; Schulder M
J Clin Neurosci; 2024 Jun; 124():15-19. PubMed ID: 38631196
[TBL] [Abstract][Full Text] [Related]
18. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
